<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317209</url>
  </required_header>
  <id_info>
    <org_study_id>SHR0410-103</org_study_id>
    <nct_id>NCT04317209</nct_id>
  </id_info>
  <brief_title>A Study of SHR0410 in Hemodialysis Patients With Pruritus</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study on Safety, Tolerability and Pharmacokinetics of SHR0410 in Hemodialysis Subjects With Moderate to Severe Pruritus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety, tolerability and pharmacokinetics of SHR0410
      in hemodialysis patients with moderate to severe pruritus
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence and severity of any adverse events that occurred between the first administration and the 48-hour period following the last administration</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate the safety and tolerability of repeated doses of SHR0410</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under drug-time curve</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak time</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak concentration</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>half-life</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent clearance rate</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent distribution volume</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of AUC0-t after the first and last administration.</measure>
    <time_frame>up to 7 days</time_frame>
    <description>To evaluate pharmacokinetic (PK) of repeated doses of SHR0410</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>SHR0410 low dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0410 medium dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SHR0410 high dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR0410</intervention_name>
    <description>administered intravenously</description>
    <arm_group_label>SHR0410 high dosage</arm_group_label>
    <arm_group_label>SHR0410 low dosage</arm_group_label>
    <arm_group_label>SHR0410 medium dosage</arm_group_label>
    <other_name>KOR agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged 18-65 (inclusive);

          2. Weight (&gt; 50 kg);

          3. Patients with end-stage renal disease receiving hemodialysis (including hemodialysis
             and hemofiltration) three times a week for at least 3 months.

          4. VAS≥4 at screening

        Exclusion Criteria:

          1. New York cardiac function classification (NYHA) ≥ level III in the current or previous
             6 months;

          2. Pruritus caused by other than end-stage renal disease or its complications..

          3. History of malignancy

          4. Any physical or mental illness or condition, as determined by the study investigator,
             that may increase the risk of participating the trial, affect the subject's compliance
             with the protocol, or affect the subject's completion of the trial

          5. Positive urine drug screening; Or a history of drug abuse;

          6. Urine test positive for nicotine;

          7. Alcohol breath test positive;

          8. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or transglutaminase
             (GGT) was 1.5 times higher than the upper limit of normal value (ULN), or total
             bilirubin was 1.5 times higher than the upper limit of normal value (ULN);

          9. Screening for hepatitis c antibody (HCVAb), syphilis antibody or human
             immunodeficiency virus (HIV) antibody positive; Or hepatitis B is active;

         10. Abnormal electrocardiogram considered inappropriate to participate in this study by
             the investigator

         11. positive for human chorionic gonadotropin (hCG) blood test

         12. A history of allergies to opioids

         13. Has used opioids within one week prior to the current visit, or cannot avoid to use
             opioids other than the study drug during the study period;

         14. Change the treatment regimen for pruritus within 14 days, or cannot avoid to change
             the treatment regimen for pruritus during the study period

         15. Received Ultraviolet phototherapy within 14 days before screening visit; Or cannot
             avoid to receive ultraviolet light therapy during the study.

         16. Change the treatment regimen of gabapentin, pregabalin, or duloxetine within 14 days
             before screening visit; Or the treatment regimen of gabapentin, pregabalin, or
             duloxetine cannot be avoided to be changed during the study period.

         17. Change the treatment regimen of medications within 14 days that may affect the
             judgment of antipruritic effect; Or the treatment regimen cannot be avoided to be
             changed during the study

         18. Using topical antipruritic drugs, such as creams and patches with moisturizing or
             antipruritic effects at present.

         19. Kidney transplantation is expected during the study period;

         20. Subjects who had Participated in this trial (defined by signing the informed consent);

         21. Subjects who had Participated in clinical trials of any other drugs within the
             previous 3 months; Or plan to participate in other drug trials during the trial
             period;

         22. Subjects who had Participated in the clinical trial of any medical device within the
             previous 3 months; Or participate in other medical device tests during the trial
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianjun Zou</last_name>
    <phone>02168868570</phone>
    <phone_ext>02168868570</phone_ext>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Yue</last_name>
    <email>yueli@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of sun yat-sen university</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Chen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

